474 related articles for article (PubMed ID: 29146555)
1. Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer.
Boonyaratanakornkit V; Hamilton N; Márquez-Garbán DC; Pateetin P; McGowan EM; Pietras RJ
Mol Cell Endocrinol; 2018 May; 466():51-72. PubMed ID: 29146555
[TBL] [Abstract][Full Text] [Related]
2. Extranuclear expression of hormone receptors in primary breast cancer.
Kim R; Kaneko M; Arihiro K; Emi M; Tanabe K; Murakami S; Osaki A; Inai K
Ann Oncol; 2006 Aug; 17(8):1213-20. PubMed ID: 16760268
[TBL] [Abstract][Full Text] [Related]
3. Estrogen and progesterone signalling in the normal breast and its implications for cancer development.
Hilton HN; Clarke CL; Graham JD
Mol Cell Endocrinol; 2018 May; 466():2-14. PubMed ID: 28851667
[TBL] [Abstract][Full Text] [Related]
4. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.
Wiebe JP; Zhang G; Welch I; Cadieux-Pitre HA
Breast Cancer Res; 2013 May; 15(3):R38. PubMed ID: 25927181
[TBL] [Abstract][Full Text] [Related]
5. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
Kim HJ; Cui X; Hilsenbeck SG; Lee AV
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
[TBL] [Abstract][Full Text] [Related]
6. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
Singhal H; Greene ME; Tarulli G; Zarnke AL; Bourgo RJ; Laine M; Chang YF; Ma S; Dembo AG; Raj GV; Hickey TE; Tilley WD; Greene GL
Sci Adv; 2016 Jun; 2(6):e1501924. PubMed ID: 27386569
[TBL] [Abstract][Full Text] [Related]
7. Sequence analysis of the DNA binding domain of the estrogen receptor gene in ER (+)/PR (-) breast cancer.
Mies C; Voigt W
Diagn Mol Pathol; 1996 Mar; 5(1):39-44. PubMed ID: 8919544
[TBL] [Abstract][Full Text] [Related]
8. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology.
Jacobsen BM; Schittone SA; Richer JK; Horwitz KB
Mol Endocrinol; 2005 Mar; 19(3):574-87. PubMed ID: 15563544
[TBL] [Abstract][Full Text] [Related]
9. Receptor mechanisms of rapid extranuclear signalling initiated by steroid hormones.
Boonyaratanakornkit V; Edwards DP
Essays Biochem; 2004; 40():105-20. PubMed ID: 15242342
[TBL] [Abstract][Full Text] [Related]
10. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells.
Pietras RJ; Márquez DC; Chen HW; Tsai E; Weinberg O; Fishbein M
Steroids; 2005; 70(5-7):372-81. PubMed ID: 15862820
[TBL] [Abstract][Full Text] [Related]
11. Mediator of ERBB2-driven cell motility (MEMO) promotes extranuclear estrogen receptor signaling involving the growth factor receptors IGF1R and ERBB2.
Jiang K; Yang Z; Cheng L; Wang S; Ning K; Zhou L; Lin J; Zhong H; Wang L; Li Y; Huang J; Zhang H; Ye Q
J Biol Chem; 2013 Aug; 288(34):24590-9. PubMed ID: 23861392
[TBL] [Abstract][Full Text] [Related]
12. Estrogen and progesterone receptors in breast cancer.
Yip CH; Rhodes A
Future Oncol; 2014 Nov; 10(14):2293-301. PubMed ID: 25471040
[TBL] [Abstract][Full Text] [Related]
13. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.
Ogba N; Manning NG; Bliesner BS; Ambler SK; Haughian JM; Pinto MP; Jedlicka P; Joensuu K; Heikkilä P; Horwitz KB
Breast Cancer Res; 2014 Dec; 16(6):489. PubMed ID: 25475897
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
Cui X; Zhang P; Deng W; Oesterreich S; Lu Y; Mills GB; Lee AV
Mol Endocrinol; 2003 Apr; 17(4):575-88. PubMed ID: 12554765
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Value of ER, PR, FR and HER-2-Targeted Molecular Probes for Magnetic Resonance Imaging in Patients with Breast Cancer.
Jin YH; Hua QF; Zheng JJ; Ma XH; Chen TX; Zhang S; Chen B; Dai Q; Zhang XH
Cell Physiol Biochem; 2018; 49(1):271-281. PubMed ID: 30138940
[TBL] [Abstract][Full Text] [Related]
16. The loss of estrogen and progesterone receptor gene expression in human breast cancer.
Lapidus RG; Nass SJ; Davidson NE
J Mammary Gland Biol Neoplasia; 1998 Jan; 3(1):85-94. PubMed ID: 10819507
[TBL] [Abstract][Full Text] [Related]
17. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
[TBL] [Abstract][Full Text] [Related]
18. Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells.
Chakravarty D; Nair SS; Santhamma B; Nair BC; Wang L; Bandyopadhyay A; Agyin JK; Brann D; Sun LZ; Yeh IT; Lee FY; Tekmal RR; Kumar R; Vadlamudi RK
Cancer Res; 2010 May; 70(10):4092-101. PubMed ID: 20460518
[TBL] [Abstract][Full Text] [Related]
19. Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas.
Tufail R; Jorda M; Zhao W; Reis I; Nawaz Z
Breast Cancer Res Treat; 2012 Feb; 131(3):743-50. PubMed ID: 21399893
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer.
Buxant F; Engohan-Aloghe C; Noël JC
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):254-7. PubMed ID: 19875955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
